We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STVN:NYSEStevanato Group S.p.A. Analysis

Data as of 2026-05-27 - not real-time

$17.87

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Stevanato Group (STVN) is trading at $17.87, just above its 20‑day SMA (17.86) but well below the 200‑day SMA (20.07), indicating a neutral longer‑term trend. Momentum metrics are mixed – RSI sits at 59 (still below overbought) while the MACD histogram is negative and the signal line is bearish, and volume has been decreasing, suggesting short‑term pressure. The stock carries a high beta of 1.62 and 30‑day volatility of 35.8%, flagging notable price swings. Fundamentally, the company posted 6.6% revenue growth, a solid operating margin of 14.2%, and a forward EPS of $0.85, yet its current PE of 30.3 exceeds the industry average of 27.4 and the DCF‑derived fair value of $10.35 points to potential overvaluation. Analysts rate the stock as a “buy” with a median target of $25, implying roughly 40% upside, but the balance sheet shows $450 M of debt against $112 M of cash and a debt‑to‑equity ratio of 29.4, raising concerns about dividend sustainability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and decreasing volume signal near‑term weakness
  • Price hovering just above support at $15.95
  • Recent earnings beat but stock price dipped on the news

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst consensus target of $25 suggests ~40% upside
  • Revenue growth of 6.6% and improving forward PE to 21
  • Strategic guidance to expand RTU cartridge production in 2027

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Secular demand for drug‑containment and delivery solutions
  • Diversified global customer base across pharma and biotech
  • Potential operational leverage from engineering segment and contract manufacturing

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin11.75%
P/E Ratio30.3
ROE9.59%
ROA5.27%
Debt/Equity29.43
P/B Ratio2.8
Op. Cash Flow$261.7M
Free Cash Flow$-57059124
Industry P/E27.4

Technical Analysis

TrendNeutral
RSI59.1
Support$15.94
Resistance$19.05
MA 20$17.86
MA 50$15.93
MA 200$20.07
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46

Valuation

Fair Value$10.35
Target Price$24.83
Upside/Downside38.97%
GradeOvervalued
TypeBlend
Dividend Yield0.35%

Risk Assessment

Beta1.62
Volatility35.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.